Panmure Gordon Analyst – Dr Mike Mitchell “This morning, Immupharma has provided an update on the Lupuzor phase III investigators meeting which was held in Paris on 11th and 12th December. With the first US sites now opened for recruitment of Lupus patients, as confirmed on the ClinicalTrials.gov website, we see the news as reflecting good momentum in its lead programme with an asset – we remind investors – fully owned by Immupharma. We look forwards to further updates during 2016”

Learning About Lupus
May is Lupus Awareness Month. It is a disease that is relatively common in the Caribbean yet many of us are unfamiliar with the condition. Lupus is an autoimmune condition that can affect almost every system